

1 **Distinct microRNA expression signatures of primary and secondary central nervous**
2 **system lymphomas**

3 Endre Sebestyén¹, Ákos Nagy², Dóra Marosvári², Hajnalka Rajnai¹, Béla Kajtár³, Beáta
4 Deák⁴, András Matolcsy^{1,2,5}, Sebastian Brandner⁶, James Storhoff⁷, Ning Chen⁷, Attila G.
5 Bagó⁸, Csaba Bödör², Lilla Reiniger^{1,9}

6

7 1, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University,
8 Budapest, Hungary

9 2, MTA-SE Momentum Molecular Oncohematology Research Group, 1st Department of
10 Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

11 3, Department of Pathology, University of Pécs, Clinical Centre, Pécs, Hungary

12 4, Department of Medical Oncology and Haematology, National Institute of Oncology,
13 Budapest, Hungary

14 5, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet,
15 Karolinska University Hospital, 171 77 Stockholm, Sweden

16 6, Division of Neuropathology, The National Hospital for Neurology and Neurosurgery,
17 University College London Hospitals NHS Foundation Trust and Department of
18 Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG
19 United Kingdom

20 7, NanoString Technologies, Seattle, WA, USA

21 8, Department of Neurooncology, National Institute of Clinical Neurosciences, Budapest,
22 Hungary

23 9, SE-NAP Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis
24 University, Budapest, Hungary

25

26 **Correspondence:** Lilla Reiniger: reiniger.lilla@med.semmelweis-univ.hu

27 1st Department of Pathology and Experimental Cancer Research, Semmelweis University,
28 Üllői út 26, Budapest, Hungary, H-1085.

29 Tel.: + 36 1 459 1500/4435, Fax: + 36 1 317 1074

30

31 **Keywords:** microRNA, PCNSL, brain lymphoma, molecular subtype

32

33 **Author contributions:** Endre Sebestyén analyzed all NanoString data, interpreted the results
34 and wrote the paper, Ákos Nagy did the RT-PCR and ddPCR validation, Dóra Marosvári
35 isolated the RNA samples, Hajnalka Rajnai revised histology, Beáta Deák contributed
36 samples and clinical data, András Matolcsy revised histology, Sebastian Brandner contributed
37 samples and clinical data, James Storhoff and Ning Chen coordinated the NanoString studies,
38 Ning Chen performed NanoString data QC and analysis, Attila G. Bagó contributed samples
39 and clinical data, Csaba Bödör designed and coordinated the study, Lilla Reiniger designed
40 and coordinated the study, contributed samples, interpreted the results and wrote the paper.
41 All authors read and approved the final version of the manuscript.

42

43

44 **Funding:** This work was funded by the Hungarian Science Foundation (OTKA-PD115792 to
45 Lilla Reiniger) and Hungarian National Research, Development and Innovation Office
46 (NKFIH) (KH17-126718 to Csaba Bödör, NVKP_16-1-2016-0004 to András Matolcsy and
47 FK-132666 to Endre Sebestyén). Furthermore, the study was supported by the Higher
48 Education Institutional Excellence Programme of the Ministry of Human Capacities in
49 Hungary within the framework of the Molecular Biology thematic programme of the
50 Semmelweis University to Csaba Bödör, the Hungarian Brain Research Program (2017-1.2.1-
51 NKP-2017-00002 to Lilla Reiniger), Semmelweis University Science and Innovation Fund
52 (STIA_18_KF to Endre Sebestyén and STIA_21_KF to Csaba Bödör), Elixir Hungary (to
53 Csaba Bödör) and the Research Grant of the University of Pécs Medical School (KA-2019-32
54 to Béla Kajtár).

55 The UK Brain Archive Information Network (BRAIN UK) is funded by the Medical
56 Research Council and Brain Tumour Research. Sebastian Brandner was partly supported by
57 the National Institute for Health Research Biomedical Research Centre's funding scheme to
58 UCLH.

59 **Acknowledgements:** We thank Rachel Bradshaw from NanoString Technologies for the
60 microRNA profiling, Mingdong Liu from NanoString Technologies for help in NanoString
61 data QC and analysis, and Zoltán Szállási for critical reading of the manuscript.

62

63

64 **Abstract**

65 Central nervous system (CNS) lymphoma is a rare and aggressive non-Hodgkin lymphoma
66 that might arise in the CNS (primary CNS lymphoma, PCNSL) or disseminates from a
67 systemic lymphoma to the CNS (secondary CNS lymphoma, SCNSL). Dysregulated
68 expression of microRNAs (miRNAs) is associated with various pathological processes and
69 miRNA expression patterns may have diagnostic, prognostic and therapeutic implications.
70 However, miRNA expression is understudied in CNS lymphomas. Here, we performed
71 expression analysis of 798 miRNAs in 73 CNS lymphoma samples using the NanoString
72 platform, followed by a detailed statistical analysis to identify potential novel biomarkers
73 characterizing subgroups and to examine differences based on their primary and secondary
74 nature, molecular subtype, mutational patterns and survival. We describe the general
75 expression patterns of miRNAs across CNS lymphoma samples and identified 31
76 differentially expressed miRNAs between primary and secondary groups. Additionally, we
77 identified 7 more miRNAs associated with a molecular subtype and 25 associated with
78 mutation status. Using unsupervised clustering methods, we defined a small but distinct
79 primary CNS lymphoma subgroup, with characteristically different expression patterns
80 compared to the rest of the cases. Finally, we identified differentially regulated pathways in
81 the above comparisons and assessed the utility of miRNA expression patterns in predicting
82 survival. Our study identifies a novel CNS lymphoma subgroup defined by distinct miRNAs,
83 proves the importance of specific miRNAs and pathways in their pathogenesis, and provides
84 the basis for future research.

85

86

87

88

89 **Background**

90 Central nervous system (CNS) lymphoma is a rare and aggressive non-Hodgkin lymphoma
91 that either arises in the CNS structures (primary CNS lymphoma, PCNSL) or disseminates
92 from a systemic lymphoma to the CNS (secondary CNS lymphoma, SCNSL). Histologically,
93 it predominantly manifests as a diffuse large B-cell lymphoma (DLBCL). Effective treatment
94 of CNS lymphomas remains a significant challenge as their molecular pathogenesis is not
95 well understood [1-4].

96 Both from a therapeutic and prognostic point of view, it is becoming increasingly important to
97 precisely define the molecular subtype of DLBCLs into germinal center B-cell (GC) type,
98 activated B-cell (ABC) type or “unclassified” (UC) cases, as described by Alizadeh *et al.* [5].
99 Patients in the ABC-type DLBCL group show an inferior outcome [5, 6] compared to the
100 other types. The fundamental difference in biology including oncogenic pathways and
101 mutation targets between GC- and ABC-type DLBCLs is also reflected in the different
102 efficacy of novel targeted therapies between these subgroups [7, 8]. A more precise, gene
103 expression-based molecular subtype assignment can be achieved from formalin-fixed paraffin
104 embedded (FFPE) tissue using the NanoString Lymphoma Subtyping Test (LST) assay
105 (NanoString Technologies, Inc., Seattle, USA) compared to the standard
106 immunohistochemical (IHC) methods. The NanoString assay also demonstrates a better
107 concordance with the gold-standard Affymetrix approach [9].

108 The discovery of microRNAs (miRNAs, miRs) has opened a new field for unraveling and
109 therapeutically targeting diseases. These small non-coding RNAs regulate diverse biological
110 processes through post-transcriptional gene expression modulation. Based on their seed
111 sequence, miRNAs bind to multiple target mRNAs, thereby promoting their degradation or
112 inhibiting translation [10-12]. Dysregulated expression of miRNAs is associated with a

113 myriad of pathological processes including hematological malignancies [13, 14], and distinct
114 miRNA expression patterns may also have diagnostic, prognostic and therapeutic implications
115 [15-19]. As miRNAs remain relatively well preserved in archival FFPE tissue specimens, they
116 are readily available as a valuable source of information in cancer tissues [20-22]. For the
117 quantification of miRNA transcripts in FFPE samples, the NanoString nCounter technology is
118 a preferable choice over quantitative reverse transcription polymerase chain reaction (RT-
119 PCR) [23, 24], with a high reproducibility similar to other platforms [25, 26]. The NanoString
120 assay also performs well in relative quantification studies [27].

121 MiRNA expression of PCNSL has been studied using different methods such as RT-PCR [28-
122 38], microarray [36, 39], *in situ* hybridization [37, 38], next-generation sequencing (NGS)
123 [35] and NanoString [38] technologies on various tissue types including brain biopsy
124 specimens (FFPE [32, 37, 39] or fresh [36]), cerebrospinal fluid (CSF) [28-31, 33, 38] and
125 peripheral blood [35], serum [34] or plasma [33]. It has been shown and further confirmed
126 that the combined detection of miR-21, miR-19b and miR-92a in CSF allowed a reliable
127 diagnosis of PCNSL. Moreover, these miRNAs emerge as promising tools in treatment
128 monitoring and follow-up [28, 29], similarly to U2 small nuclear RNA fragments [30]. In
129 addition, plasma miR-21 may serve as a diagnostic [33], and serum miR-21 both as a
130 diagnostic and prognostic marker for PCNSL [34]. Other miRNAs with prognostic value in
131 PCNSL include miR-151a-5p and miR-151b, together with 10 additional miRs [35]. CSF
132 levels of miR-21 may have potential as a predictor of chemotherapeutic effect [33].
133 Measuring miR-30c in the CSF can differentiate between PCNSL and SCNSL, as elevated
134 levels of miR-30c have pathobiological significance in SCNSL [31]. A recent microarray
135 study found a couple of miRNAs with positive or negative prognostic significance in PCNSL
136 [36]. It has also been demonstrated, that PCNSL shows different miRNA expression profiles
137 compared with nodal or testicular DLBCL [32, 37, 39].

138 In this study, we performed expression profiling of 798 human miRNAs in 73 FFPE brain
139 biopsy samples of primary and secondary CNS lymphomas using the NanoString platform,
140 followed by a bioinformatics analysis to reveal changing expression signatures. We aimed to
141 identify potential novel biomarkers characterizing subgroups among brain lymphomas, as
142 well as to examine differences based on their primary and secondary nature, molecular
143 subtype, mutational patterns and survival.

144

145

146 **Methods**

147 ***Sample collection and patient information***

148 FFPE brain biopsy specimens of 64 patients with PCNSL and 9 patients with SCNSL were
149 analyzed in this study. Tissue samples were obtained from three centers: (i) 1st Department of
150 Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary;
151 (ii) Department of Pathology, University of Pécs, Pécs, Hungary and (iii) Division of
152 Neuropathology, The National Hospital for Neurology and Neurosurgery, University College
153 London Hospitals, United Kingdom, through the UK Brain Archive Information Network
154 (BRAIN UK). Permissions to use the archived tissue have been obtained from the Local
155 Ethical Committee (TUKEB-1552012) and from BRAIN UK (Ref.: 16/018), and the study
156 was conducted in accordance with the Declaration of Helsinki.

157 Information on the molecular subtypes determined by the Research Use Only version of the
158 NanoString LST-assay (NanoString Technologies, Inc., Seattle, USA) and on the mutational
159 status identified by ultra-deep NGS of 14 target genes as described previously [40] are
160 summarized in Supplementary file 1, together with clinical and survival data. Survival data
161 was available in 54 PCNSL and 9 SCNSL cases. The PCNSL cases consisted of 78.1%
162 (50/64) ABC, 15.6% (10/64) GC and 6.3% (4/64) UC molecular subtypes. Among the
163 SCNSL cases, 44.4% (4/9) were classified as ABC- and 55.6% (5/9) as GC-subtypes (Figure
164 1A).

165

166 ***MicroRNA profiling using the NanoString platform***

167 RNA isolation from 64 PCNSL and 9 SCNSL samples was performed using the
168 RecoverAll™ kit (Life Technologies/Ambion, Inc, Foster City USA) according to the
169 manufacturer's instructions. Approximately 100 ng of total RNA from each sample was
170 analyzed using the Human v3 miRNA expression assay kit, following manufacturer's

171 instructions (NanoString Technologies, Inc., Seattle, USA). The Human v3 miRNA assay
172 covers 98% of miRNA sequences found in miRBase v22, including 798 probes that recognize
173 human miRNAs and 29 assay control probes. Raw data were pulled from digital analyzer and
174 imported into nSolver4.0 (NanoString™) for data quality check. Data sets that passed all QC
175 checks (including imaging quality, binding density, positive control linearity and limit of
176 detection) were exported as a .csv file for downstream statistical analysis. Raw miRNA
177 counts for all samples are available in the GSE162956 dataset at NCBI GEO.

178

179 *NanoString data normalization*

180 Raw NanoString read counts and clinical information was imported into the R statistical
181 environment (version 3.5.1). We discarded human miRNAs with extremely low expression
182 (read count ≤ 1 in more than 60 samples) before normalization, resulting in 781 human
183 miRNAs, besides the control probes and housekeeping genes. Data normalization was done
184 with the NanoStringNorm package (version 1.2.1) [41] using the following options:
185 CodeCount = “geo.mean”, Background = “mean.2sd”, SampleContent =
186 “housekeeping.geo.mean”, OtherNorm = “quantile”. We used the ath, cel, osa and NEG
187 miRNA classes as negative controls, the POS class as positive controls, the *ACTB*, *B2M*,
188 *GAPDH*, *RPL19* and *RPLP0* genes as housekeeping genes, and everything else as endogenous
189 miRNAs. During the initial data assessment, we considered those miRNAs expressed, that
190 had a larger normalized expression value than the lowest positive control (Addt 2).
191 Additionally, we calculated the minimum, maximum and average expression of all miRNAs
192 across all samples, together with the number of samples where a miRNA was expressed
193 across all samples using the normalized expression values. Finally, we calculated the
194 minimum, maximum, average and median values for the PCNSL and SCNSL samples

195 separately. Based on the median expression values we ranked the miRNAs and categorized
196 them into 15 separate expression groups.

197

198 ***Differential expression analysis***

199 We used the limma package (version 3.38.3) for differential expression [42]. We included the
200 primary or secondary category, the molecular subtype, origin of sample (institute or
201 department), degradation time and NanoString scan dates in the linear model as covariates
202 during differential expression analysis. We converted the normalized read counts with the
203 voom [43] function of limma, fitted the linear model with the lmFit function and calculated p-
204 values with the eBayes function [44]. The raw p-values were false discovery rate (FDR)
205 adjusted using the Benjamini-Hochberg method. We considered miRNAs differentially
206 expressed with FDR adjusted p-value < 0.05 and absolute log₂ fold change between
207 conditions > 1 (Supplementary file 3).

208 We carried out a number of comparisons between different sample groups. First, we
209 calculated differentially expressed miRNAs between the primary and secondary samples.
210 Additionally, we calculated differentially expressed miRNAs between the different molecular
211 subtypes, within the primary samples. This included the GC vs ABC, UC vs ABC and GC vs
212 UC comparisons. Finally, we calculated differences between the different sample groups
213 stratified by mutation status, using the *CARD11*, *CCND3*, *CD79B*, *CSMD2*, *CSMD3*, *IRF4*,
214 *KMT2D*, *MYC*, *MYD88*, *PAX5*, *PIMI*, *PRDMI* and *TP53* genes (Supplementary file 3).

215

216 ***Principal component analysis and unsupervised clustering***

217 During the principal component analysis, we used the normalized and voom transformed data,
218 additionally removing the potential batch effects of the institute, scan date and degradation
219 time with the removeBatchEffect function of the limma package. We calculated the principal

220 components with the `prcomp` R function with the `scale. parameter` set to `TRUE`, and plotted
221 the first and second principal components.

222 During the binary hierarchical clustering of the samples, we used the `voom` transformed,
223 normalized read counts of all endogenous miRNAs, after removing the potential batch effects
224 of the institute, scan date and degradation time with the `removeBatchEffect` function of the
225 `limma` package. First, we binarized the expression values [45] with a cut-off of 12. All
226 miRNAs below this threshold were considered not expressed, while the rest was considered
227 expressed. Using the expressed/not expressed status of the miRNAs across all samples, we
228 calculated sample distances using the `dist` function from R, with the binary method, and did a
229 hierarchical clustering using the `hclust` function, with the `ward.D2` method. We manually
230 defined a “small” and a “big” cluster of samples (Supplementary file 4), and carried out a
231 Fisher-test, using a 2x2 contingency table (expressed/not expressed and small/big cluster) to
232 check for miRNAs whose expression is associated with the small and big clusters
233 (Supplementary file 5). The Fisher-test p-values were FDR adjusted using the Benjamini-
234 Hochberg method and miRNAs with FDR adjusted p-value < 0.05 were considered associated
235 with the cluster type. We repeated the binary hierarchical clustering using only the primary
236 samples without changing any other parameter.

237 Additionally, we performed a k-means clustering on the data, where we also used the `voom`
238 transformed, normalized read counts of all endogenous miRNAs after removing the potential
239 batch effects of the institute, scan date and degradation time with the `removeBatchEffect`
240 function of the `limma` package. We used `kmeans` function of R, with the `iter.max = 1000`
241 parameter and setting the cluster number to 4. We clustered both the samples and the
242 miRNAs. During data visualization we dropped the largest miRNA cluster as it mainly
243 contained miRNAs that were not expressed in most samples or had a very low expression

244 level. We repeated the k-means clustering using only the primary samples without changing
245 any other parameter.

246

247 *miRNA pathway enrichment analysis*

248 We used the miRNet database (accessed and downloaded on 2019-08-29) to collect putative
249 targets of the differentially expressed miRNAs [46]. We downloaded all gene and lncRNA
250 targets of these miRNAs from bone-marrow or brain tissue-based experiments. We
251 considered a gene up- or downregulated if at least two of its putative regulators from miRNet
252 were differentially expressed in the opposite direction in a specific tissue type. For example,
253 the AGO1 gene was considered downregulated in the secondary vs primary comparison, as 7
254 of its regulatory miRNAs defined in miRNet were upregulated in the secondary vs primary
255 comparison based on the NanoString analysis. Based on this filtering criteria, only bone
256 marrow-based mRNA interactions were considered for further downstream analysis.

257 Additionally, we downloaded version 7 of the MSigDB gene sets (H, C2 – C7) [47] and did a
258 Fisher-test using a 2x2 contingency table as follows: genes were either part of a gene
259 collection or not, and based on the miRNet analysis they were putatively differentially
260 expressed or not. The Fisher-test p-values were FDR adjusted using the Benjamini-Hochberg
261 method and gene collections with FDR adjusted p-value < 0.05 were considered enriched in a
262 specific comparison (secondary vs primary, etc) (Supplementary file 6).

263

264 *Survival analysis*

265 Survival data was available for 63 patients with the overall survival in months, last follow-up
266 date, and survival status. We used only the 54 primary CNS lymphoma cases during this
267 analysis, and stratified patients according to the binary expression status of the investigated
268 miRNAs, or the big/small cluster classification. We used the survival package (version 2.44-

269 1.1) [48] to create Surv objects in R and calculated log-rank test based p-values using the
270 survminer (version 0.4.6) [49] package. The log-rank p-values were FDR adjusted using the
271 Benjamini-Hochberg method (Supplementary file 7).

272

273 *Validation of NanoString miRNA expression data*

274 10 miRNAs with significant differential expression among subgroups were selected
275 (Supplementary file 8 and 9) based on NanoString expression data. Additionally, 3 miRNAs
276 with stable expression in the cohort were used as endogenous control.

277 *Validation with droplet digital PCR*

278 The selected samples were individually reverse-transcribed with the TaqMan™ MicroRNA
279 Reverse Transcription Kit (Applied Biosystems, USA) following manufacturer's instructions.
280 Hundred ng miRNA from each selected sample was reverse-transcribed with specific
281 TaqMan™ miRNA assays (Applied Biosystems, USA) in ProFlex Thermal Cyclers (Applied
282 Biosystems, USA) using the following parameter values: 16°C for 30 min, 42°C for 30 and
283 85°C for 5 min. cDNAs were further diluted with 50 ul nuclease-free water to obtain a final
284 volume of 77 ul. 10 ul diluted cDNA sample were used in the subsequent droplet digital PCR
285 (ddPCR) reactions with 1 ul of the specific TaqMan™ miRNA assays and 11 ul of ddPCR
286 Supermix for Probes (No dUTP) (Bio-Rad Laboratories, USA). Following droplet generation,
287 target miRNAs were amplified in a C1000 Touch Thermal Cycler (Bio-Rad Laboratories,
288 USA) with parameters as follows: 10 min at 95°C for enzyme activation, followed by 40
289 cycles of denaturation at 94°C for 30 s and 1 min annealing/extension at 55°C, enzyme
290 deactivation step set at 98°C for 10 min, and a final hold step at 4°C for an infinite time
291 period. Results were analyzed using the QuantaSoft software (version 1.7; Bio-Rad, USA).
292 All ddPCR reactions were performed with the detection of adequate events (>10000 droplets
293 per sample). Results were determined in copy number per ul.

294 *Validation with quantitative RT-PCR*

295 Further NanoString miRNA expression data validation was completed with quantitative RT-
296 PCR. Reverse Transcription was performed as described above with the exception that each
297 miRNA target was individually reverse-transcribed with an endogenous control miRNA. Five
298 ul of the cDNA samples were amplified in duplicates using 1.5 ul of the target and
299 endogenous control specific TaqMan™ miRNA assays with 7.7 ul 2x TaqMan puffer
300 (Applied Biosystems, USA) and 10.5 ul nuclease-free water on a Quantstudio 3 Real-Time
301 PCR system (Applied Biosystems, USA). Ct values for sample target and endogenous
302 miRNAs were determined as the average Ct value of the duplicates. Δ -Ct values were
303 obtained extracting Ct values of endogenous control miRNAs from the Ct values of target
304 miRNAs, which were subsequently used for statistical analysis.

305

306

307 **Results**

308 *General miRNA expression patterns in CNS lymphomas*

309 The NanoString panel contained 798 endogenous, 5 housekeeping genes (*ACTB*, *B2M*,
310 *GAPDH*, *RPL19*, *RPLP0*), 9 positive and 16 negative controls. Based on the normalized
311 expression values, almost half of the investigated miRNAs (381) were not expressed in any
312 sample, and 54 were expressed only in one. On the other hand, 12 miRNAs were expressed in
313 72 and 2 miRNAs in all 73 samples (Supplementary file 2).

314 We compared the median expression of endogenous miRNAs between PCNSL and SCNSL
315 samples (Figure 1B). miRNAs with a non-zero median expression in both groups were highly
316 correlated (Spearman correlation 0.89). We found 676 and 661 miRNAs in PCNSL and
317 SCNSL respectively, that had rank in the bottom 10 % based on their median expression. On
318 the other hand, hsa-miR-4454+hsa-miR-7975 is an extreme outlier, with a larger median
319 expression than most of the positive controls. We noticed that the hsa-miR-4454 expression
320 detected by NanoString might be confounded by the expression of tRNA^{His}, as the miRNA is
321 identical to the 3' end of this tRNA [50].

322

323 *Differential miRNA expression between primary and secondary CNS lymphomas and*
324 *molecular subtypes*

325 We analyzed differential expression patterns of the miRNAs between PCNSL and SCNSL
326 cases and different molecular subtypes using the limma R package, after removing known
327 confounding factors. With an absolute log₂ fold change > 1 and FDR value < 0.05 cut-off, we
328 found 31, 4 and 3 differentially expressed miRNAs between PCNSL and SCNSL cases, GC
329 and ABC subtypes, and UC and ABC subtypes, respectively (Figure 2A, Table 1 and
330 Supplementary file 3). Twenty-eight miRNAs showed increased and three showed decreased

331 expression in SCNSL compared to PCNSL. Three miRNAs showed lower and one miRNA
332 higher expression in GC compared to ABC cases. All three differentially expressed miRNAs
333 showed lower levels in UC compared to ABC subtypes (Supplementary file 3).

334

335 ***miRNA expression profile association to mutation status***

336 We assessed whether miRNA expression profiles were associated with the mutation status of
337 specific genes. We found 8 differentially expressed miRNAs associated with the mutation
338 status of the *PRDMI* gene, and one miRNA associated with the mutation status of *MYC* and
339 *CARD11* genes (Figure 2B, Table 1 and Supplementary file 3).

340 We also identified 8, 5 and 2 differentially expressed miRNAs in cases with *PAX5*, *CSMD3*
341 and *CSMD2* mutations. However, there were only two samples harboring mutation in each of
342 these genes, therefore, the results must be considered with caution (Supplementary file 3).

343

344 ***Unsupervised clustering of miRNA expression data***

345 We checked if the data grouped according to disease characteristics using principal
346 component analysis (PCA). The PCA results did not indicate the presence of distinct groups
347 based on disease subtype (primary or secondary) or molecular subtype (Figure 3).
348 Additionally, the samples do not cluster based on RNA isolation group, place of origin,
349 scanning date, degradation time, % tumor content, age or sex (Supplementary Figure 1 – 8).
350 As we could not define any specific grouping of samples based on this analysis, we
351 investigated the miRNA expression patterns further, using additional clustering methods.

352 First, we did a binary clustering of the data (Figure 4), where we only considered the
353 expressed/not expressed status of miRNAs. Based on the binary clustering, two sample

354 groups become apparent. A small group, consisting of 8 samples are clearly distinct from the
355 rest of the cohort (Supplementary file 4). The binary expression patterns of this group are
356 markedly different from the larger group. For example, the hsa-miR-93-5p and hsa-let-7d-5p
357 miRNAs were not expressed in any samples from the small cluster, while the hsa-miR-181a-
358 5p miRNA was expressed only in one sample. These miRNAs were expressed only in a small
359 fraction of the large cluster. Considering these expression patterns, we carried out a
360 systematic analysis and validated if the expression of specific miRNAs is significantly
361 associated with the small and large groups using a Fisher test. Based on the test results, we
362 found 19 miRNAs, whose expression patterns are associated with the clusters (Supplementary
363 file 5). Interestingly, we only found miRNAs, whose lack of expression was associated with
364 the small cluster, and did not find any, whose presence of expression was associated with the
365 same cluster. Based on these patterns, we initially thought that the small cluster might be the
366 result of a particularly bad quality sample group or strong technical bias. However, based on
367 the normalized, batch-corrected PCA analysis (Supplementary Figures 1-8) of the expression
368 data, this does not seem to be true. The cluster remains even after correcting for all known
369 technical biases, and also does not seem to be associated with age or sex.

370 After the binary clustering analysis, we repeated sample clustering using a k-means based
371 method and instead of the binary expression data, we used normalized expression values
372 (Figure 5). Based on visual inspection, we decided to use 4 clusters for the k-means
373 algorithm, both for the sample and the miRNA level analysis. Interestingly, the second largest
374 k-means sample cluster (SCluster1) consisting of 10 samples, partially overlaps with the
375 “small” cluster defined in the binary expression analysis (Supplementary file 4). In summary,
376 both the binary expression clustering and the k-means clustering defined a small set of
377 samples with markedly distinct miRNA expression patterns from the rest.

378 After inspecting the miRNA k-means clusters, we noticed that the expression of miRNAs in
379 the second largest cluster (MCluster1) in SCluster1 is low for most of the samples. We
380 checked the overlap of MCluster1 miRNAs with the 19 miRNAs that had significantly
381 different binary expression in the previous analysis. All of the 19 miRNAs were present in the
382 new k-means based cluster. Therefore, MCluster1 contains those miRNAs whose expression
383 pattern defines the small sample cluster seen in all of the above analysis.

384 Repeating both analyses using only PCNSL samples lead to similar results, with the only
385 difference being that the “small” binary cluster contained an additional sample (sample no.
386 33) (Supplementary Figures 9 and 10).

387

388 ***Pathway enrichment of differentially expressed miRNAs***

389 After the differential expression analysis, we asked if specific pathways might be up- or
390 downregulated in a specific comparison. Assuming that the differential regulation of a
391 specific miRNA will lead to the differential regulation of its target mRNAs in the opposite
392 direction, we carried out a pathway enrichment analysis, based on validated miRNA-mRNA
393 interactions from the miRNET database. Due to the low number of differentially expressed
394 miRNAs, we were able to do this analysis only in the case of SCNSL vs PCNSL and *PRDMI*
395 mutated vs non-mutated comparisons. Focusing on the hallmarks (H) gene sets of MSigDB,
396 we found several pathways that are putatively downregulated in these cases (Figure 6 and
397 Supplementary file 6). The G2M checkpoint, PI3K-AKT-MTOR signaling, TGF-beta
398 signaling pathways, MYC target and androgen response genes were downregulated in both
399 comparisons besides a number of other pathways or gene sets. Additionally, in the SCNSL vs
400 PCNSL comparison TNF-alpha signaling, apoptosis and UV response genes, the P53 pathway
401 and E2F target genes were also downregulated.

402 We carried out a similar analysis using the 19 miRNAs defined during the binary clustering,
403 that are not expressed in our “small cluster”. However, in this case, as the miRNAs are not
404 expressed in the small sample cluster, the associated enriched pathways are putatively
405 upregulated in the same samples. Pathways include the unfolded protein response, connected
406 to cellular stress, the P53 and MTORC1 signaling pathways, the epithelial to mesenchymal
407 transition or the hypoxia gene sets and UV response genes.

408 Additional, more detailed results for the SCNSL vs PCNSL, *PRDMI* mutated vs non-mutated
409 and “small cluster” analysis using the C2 – C7 gene sets are available in Supplementary file 6.

410

411 ***miRNA expression profile association to survival characteristics***

412 Finally, we asked whether the expression profile of specific miRNAs is associated to patient
413 survival. We stratified patients according to the binary expression status of miRNAs and
414 using the log-rank test, calculated the significance of overall survival (OS) differences
415 between groups (Supplementary file 7) including both PCNSL and SCNSL samples. The only
416 miRNA showing difference was hsa-miR-4488, with an FDR of 0.022 (Supplementary Figure
417 11 and 12) where expression of the miRNA was associated with worse survival. Median
418 survival for patients with “Expressed” or “Not expressed” status of hsa-miR-4488 was one
419 and 14 months, respectively. Repeating the analysis with only PCNSL samples
420 (Supplementary file 7), we found no significant differences between groups after FDR
421 correction. hsa-miR-18a-5p had the lowest FDR value (0.12). Of note, the survival analysis is
422 hampered by the relatively low number of cases and the heterogeneous nature of the treatment
423 regimens applied in this cohort.

424

425 ***Validation of NanoString results***

426 Based on the differential expression results, we selected a number of miRNAs for additional
427 validation. We used quantitative RT-PCR and ddPCR for different miRNAs. (Supplementary
428 file 8). Using the RT-PCR Δ -Ct values and the ddPCR counts, we correlated the validation
429 results with the original and normalized NanoString read counts (Supplementary file 9). RT-
430 PCR Δ -Ct values are expected to demonstrate a high negative correlation, while ddPCR
431 counts are expected to show a high positive correlation with NanoString read counts or
432 normalized expression values. We validated hsa-miR-411-5p and hsa-miR-32-5p using RT-
433 PCR, where the correlation of Δ -Ct values with the normalized read counts was ≤ -0.6 .
434 Additionally, we validated hsa-let7g-5p, hsa-miR-191-5p and hsa-miR-379-5p using ddPCR
435 where the correlation of ddPCR read counts with the NanoString read counts was ≥ 0.6 ,
436 besides hsa-miR-411-5p where the correlation of normalized read count with ddPCR counts
437 was 0.67 and the correlation of the original NanoString read count with the ddPCR count was
438 0.47.

439

440

441 **Discussion**

442 CNS lymphomas represent a considerable clinical challenge, as their molecular pathogenesis
443 is poorly explored. CNS lymphomas are difficult to investigate as they are rare, and usually
444 small biopsies are obtained for diagnostic purposes, which may not be sufficient for further
445 analyses [3, 4] in many cases. Moreover, the majority of these biopsies are archived as FFPE
446 tissue blocks, which suffer from degradation of macromolecules [51-56]. However, miRNAs
447 provide a robust signal and can be stably extracted from FFPE samples [20-22], making them
448 ideal cancer biomarkers. They are also promising targets for molecular therapy in cancer, due
449 to their role as oncomiRs or tumor-suppressors [57-59]. The NanoString nCounter technology
450 allows direct quantitation of hundreds of miRNA transcripts from FFPE tissues with
451 outstanding performance, therefore it may be a preferable choice over other transcriptomic
452 methods [23-26].

453 Previous expression studies of PCNSL revealed various miRNAs with a potential diagnostic
454 [28, 29, 31, 33, 34], prognostic [34-36] or predictive [33] value. These datasets were
455 generated by different methods, and used diverse patient-derived sample types and control
456 tissues [28-39], thus being difficult to synthesize and integrate. Moreover, most studies
457 examined only a few miRNAs [28-30, 33, 34, 37] on a limited number of CNS lymphoma
458 cases [28, 29, 32-39]. There is only a single study in the literature discussing the miRNA
459 expression differences between PCNSL and SCNSL [31]. The authors demonstrated in CSF
460 samples that miR-16, miR-30b, miR-30c, miR-191 and miR-204 were upregulated and miR-
461 222 was downregulated in SCNSL, with miR-30c showing the largest expression difference
462 [31].

463 In this study, we performed expression profiling of 798 human miRNAs in a large number of
464 CNS lymphoma cases. We compared the miRNA expression patterns of FFPE brain biopsy

465 specimens of primary and secondary CNS lymphomas to minimize the tissue bias that may
466 well be presented with the examination of systemic (nodal) DLBCL. We used the NanoString
467 platform, which is a reliable method for miRNA expression analysis of FFPE tissues [23-27].
468 We identified 28 up- and 3 downregulated miRNAs in SCNSL compared with PCNSL (Table
469 1). Out of these, 23 up- and all 3 downregulated miRNAs are completely novel and until now,
470 were not described in the context of CNS lymphomas. Reassuringly, the remaining miRNAs
471 described in the literature have similar expression patterns to our results. Amongst the already
472 described miRNAs, we found miR-30c-5p, that is significantly increased in CSF samples of
473 patients with SCNSL compared with PCNSL [31]. In general, miR-30c-5p has a tumor-
474 suppressive role in cancer pathogenesis, and shows low expression in various malignancies
475 (reviewed in [60]) which is in line with our findings (median expression: 11.18 and 0; rank:
476 137 and 147 in SCNSL and PCNSL samples, respectively) (Supplementary file 2). Its
477 significant lower expression in PCNSL may contribute to their more aggressive behavior.
478 Multiple studies have found higher expression of miR-21, a well-known oncomiR [61], both
479 in PCNSL and DLBCL cases compared to controls [16, 28, 29, 33, 34, 62-66]. In our study,
480 miR-21-5p generally showed high expression (median expression: 3278.55 and 2926.61;
481 rank: 16 and 17 in SCNSL and PCNSL samples, respectively) with a significant increase in
482 SCNSL cases. Higher expression of miR-21 has also been associated with worse overall
483 survival in DLBCL patients [67]. We found 3 members of the miR-17-92 cluster (miR-19a-
484 3p, miR-18a-5p and miR-106b-5p) to be upregulated in SCNSL compared with PCNSL, with
485 a moderately high overall expression (median expression: 606.62 and 58.34, 1088.28 and
486 383.75, and 763.30 and 263.06; rank: 70 and 94, 52 and 72, and 62 and 75, respectively in
487 SCNSL and PCNSL samples). This miRNA cluster has a strong oncogene activity in various
488 malignancies including DLBCL [68-71]. Higher expression of miR-18a was found to be
489 associated with a shorter overall survival in DLBCL [72]. Previous studies demonstrated

490 other members of the miR-17-92 cluster (miR-17-5p and miR-20a) to be upregulated in
491 PCNSL compared with nodal DLBCL [32, 37]. Moreover, high levels of miR-19b-1 and miR-
492 92a-1 were detected in the CSF of PCNSL patients [28, 29].

493 Regarding the molecular subtypes, cases in the ABC group showed significantly higher
494 expression of miR-155-5p, miR-222-3p and miR-522-3p and lower expression of miR-92a-3p
495 compared with the GC group. In line with our results, higher expression of miR-155-5p [16,
496 19, 64, 65, 71, 73-76] and miR-222-3p [18, 71, 73] has already been associated with the ABC
497 subtype in DLBCL. We found that the ABC molecular subtype also correlated with higher
498 miR-522-3p, miR-454-3p and miR-455-5p expression compared with the UC subgroup.

499 This is the first study demonstrating differentially expressed miRNAs in association with the
500 mutational status of the *PRDMI*, *MYC* and *CARD11* genes in CNS lymphomas. According to
501 the literature, the only miRNA that has already been connected to any of these genes is miR-
502 30a-5p, which directly targets *PRDMI* and modulates the WNT/beta-catenin pathway [77].
503 However, this association is not connected to the mutational status of *PRDMI* itself.

504 It is widely known, that the different miRNA profiling platforms do not perform consistently
505 [24-27]. Nevertheless, we successfully validated the observed expression patterns of miR-
506 148b-3p, miR-32-5p, miR-411-5p and miR-379-5p by ddPCR and/or RT-PCR methods.

507 Based on our data, pathway enrichment analysis revealed several downregulated pathways
508 and gene sets in SCNSL compared with PCNSL. Additionally, *PRDMI* mutation was also
509 associated with the downregulation of several pathways. Even though the evidence is
510 circumstantial, as we did not directly measure the differential regulation of the genes
511 comprising a pathway, but only their regulators, these pathways might be attractive targets for
512 future drug development. The constitutive activation of NF- κ B was already described in the
513 literature [78-80] for DLBCL, apart from the activation of the PI3K-MTOR-AKT [79-81].

514 Based on our results, these pathways are generally more active in PCNSL compared to
515 SCNSL and drugs [82] available to target these pathways might be more effective for a
516 selection of PCNSL cases. The unfolded protein response pathway was similarly upregulated
517 in PCNSL cases. This pathway is considered as a general pro-survival mechanism for cancer
518 cells [83], and small molecule inhibitors targeting the pathway are becoming available,
519 suggesting a possible therapeutic target in PCNSL, as these lymphomas might be more
520 sensitive to treatment. Additional upregulated pathways in the PCNSL vs SCNSL comparison
521 include protein secretion, the p53 pathway, MYC target genes, the G2M checkpoint, E2F
522 transcription factor target genes, apoptosis genes, and genes related to androgen response.
523 Considering that PCNSL is a rare and aggressive disease and the prognosis is poor [84], the
524 pathways and molecular mechanisms analyzed in this study might be considered as novel
525 drug targets.

526 Considering the pathway level changes in *PRDM1* mutated samples, some drugs might be
527 more effective in patients without *PRDM1* mutations. The TGF-Beta signaling, the PI3K-
528 MTOR-AKT, MYC target genes, G2M checkpoint genes and androgen response genes are all
529 downregulated in samples with *PRDM1* mutation, therefore the efficiency of their inhibitors
530 might be decreased [80, 82, 85].

531 Intriguingly, principal component analysis (PCA) showed no clustering of cases according to
532 either disease characteristics or subtypes even after accounting for the various batch effects
533 and biases. Subsequent binary clustering of the cases according to miRNA expression
534 (expressed or not expressed) revealed a small group of 8 samples clearly separating from the
535 rest of the cohort. Additional sample clustering using a k-means based method with
536 normalized expression values defined a sample cluster (SCluster1) consisting of 10 samples.
537 Five samples from SCluster1 also overlapped with the small cluster defined in the binary
538 expression analysis. Taken together, unsupervised clustering methods defined a small set of

539 samples with markedly distinct miRNA expression patterns. Interestingly, the lack of
540 expression of 19 miRNAs was found to be associated with the small cluster in the binary
541 clustering analysis. Moreover, all of these 19 miRNAs were part of a miRNA k-means cluster
542 (MCluster1) in SCluster1. Pathway enrichment analysis shows similar pattern in this small
543 distinct set of samples to PCNSL, with even more pronounced changes compared to the
544 SCNSL vs PCNSL analysis. The WNT/beta-catenin pathway activated here, was described as
545 activated in PCNSL [86], and the small set of samples defined here might be a distinct
546 PCNSL subgroup where the pathway can be efficiently targeted with Wnt inhibitors [87].
547 Based on these results, this is a well-defined sample group within the PCNSL cases
548 contributing significantly to the distinct expression patterns between PCNSL and SCNSL.

549 Survival analysis of all cases using the binary expression data showed miR-4488 to be
550 significantly associated with a worse overall survival, however, we did not find any
551 association when analyzing PCNSL samples solely. It is important to highlight that these
552 results are limited by the modest number of cases and the heterogeneous nature of the
553 treatment regimens applied in this cohort.

554 **Conclusions**

555 Our study identifies a novel CNS lymphoma subgroup defined by distinct miRNA expression
556 patterns, describes putative subtype and cell-of-origin biomarkers, and proves the importance
557 of specific miRNAs and pathways in CNS lymphoma pathogenesis. These results provide the
558 basis for future research in the area of CNS lymphomas.

559

560 **Declarations**

561 *Ethics approval and consent to participate*

562 Permissions to use the archived tissue have been obtained from the Local Ethical Committee
563 (TUKEB-1552012) and from BRAIN UK (Ref.: 16/018), and the study was conducted in
564 accordance with the Declaration of Helsinki.

565 *Consent for publication*

566 Not applicable.

567 *Availability of data and materials*

568 The datasets supporting the conclusions of this article are included within the article, its
569 additional files and at the NCBI GEO database with accession number GSE162956.

570 *Competing interests*

571 The authors declare the following competing interest. James Storhoff and Ning Chen were
572 employees of NanoString Technologies when the original NanoString analyses were carried
573 out. James Storhoff is currently an employee of Veracyte. Ning Chen is currently an
574 employee of Adaptive Biotechnologies.

575

576

577 References

- 578 1. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M,
579 Iraqi W, Sautes-Fridman C *et al*: **A uniform activated B-cell-like immunophenotype might**
580 **explain the poor prognosis of primary central nervous system lymphomas: analysis of 83**
581 **cases.** *Blood* 2006, **107**(1):190-196.
- 582 2. Liu J, Wang Y, Liu Y, Liu Z, Cui Q, Ji N, Sun S, Wang B, Wang Y, Sun X *et al*:
583 **Immunohistochemical profile and prognostic significance in primary central nervous**
584 **system lymphoma: Analysis of 89 cases.** *Oncol Lett* 2017, **14**(5):5505-5512.
- 585 3. Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT: **Comprehensive**
586 **Approach to Diagnosis and Treatment of Newly Diagnosed Primary CNS Lymphoma.** *Neuro*
587 *Oncol* 2018.
- 588 4. Hilal T: **Primary central nervous system lymphoma: Consensus, controversies, and future**
589 **directions.** *ADVANCES IN CELL AND GENE THERAPY*, n/a(n/a):e82.
- 590 5. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T,
591 Yu X *et al*: **Distinct types of diffuse large B-cell lymphoma identified by gene expression**
592 **profiling.** *Nature* 2000, **403**(6769):503-511.
- 593 6. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: **A gene expression-based**
594 **method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.** *Proc Natl*
595 *Acad Sci U S A* 2003, **100**(17):9991-9996.
- 596 7. Karmali R, Gordon LI: **Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an**
597 **Approach of Precision Therapy.** *Curr Treat Options Oncol* 2017, **18**(2):11.
- 598 8. Sujobert P, Salles G, Bachy E: **Molecular Classification of Diffuse Large B-cell Lymphoma:**
599 **What Is Clinically Relevant?** *Hematol Oncol Clin North Am* 2016, **30**(6):1163-1177.
- 600 9. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan
601 WC, Connors JM *et al*: **Determining cell-of-origin subtypes of diffuse large B-cell lymphoma**
602 **using gene expression in formalin-fixed paraffin-embedded tissue.** *Blood* 2014,
603 **123**(8):1214-1217.
- 604 10. Bartel DP: **MicroRNAs: target recognition and regulatory functions.** *Cell* 2009, **136**(2):215-
605 233.
- 606 11. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: **Prediction of mammalian**
607 **microRNA targets.** *Cell* 2003, **115**(7):787-798.
- 608 12. Brennecke J, Stark A, Russell RB, Cohen SM: **Principles of microRNA-target recognition.** *PLoS*
609 *Biol* 2005, **3**(3):e85.
- 610 13. Di Marco M, Ramassone A, Pagotto S, Anastasiadou E, Veronese A, Visone R: **MicroRNAs in**
611 **Autoimmunity and Hematological Malignancies.** *Int J Mol Sci* 2018, **19**(10).
- 612 14. Lawrie CH: **MicroRNAs in hematological malignancies.** *Blood Rev* 2013, **27**(3):143-154.
- 613 15. Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, Jackson AL: **Cobomarsen, an**
614 **oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to**
615 **reduce cellular proliferation and survival in cutaneous T-cell lymphoma.** *Br J Haematol*
616 2018, **183**(3):428-444.
- 617 16. Caramuta S, Lee L, Ozata DM, Akcakaya P, Georgii-Hemming P, Xie H, Amini RM, Lawrie CH,
618 Enblad G, Larsson C *et al*: **Role of microRNAs and microRNA machinery in the pathogenesis**
619 **of diffuse large B-cell lymphoma.** *Blood Cancer J* 2013, **3**:e152.
- 620 17. Roehle A, Hoefig KP, Reptsilber D, Thorns C, Ziepert M, Wesche KO, Thiery M, Loeffler M,
621 Klapper W, Pfreundschuh M *et al*: **MicroRNA signatures characterize diffuse large B-cell**
622 **lymphomas and follicular lymphomas.** *Br J Haematol* 2008, **142**(5):732-744.
- 623 18. Montes-Moreno S, Martinez N, Sanchez-Espirdion B, Diaz Uriarte R, Rodriguez ME, Saez A,
624 Montalban C, Gomez G, Pisano DG, Garcia JF *et al*: **miRNA expression in diffuse large B-cell**
625 **lymphoma treated with chemoimmunotherapy.** *Blood* 2011, **118**(4):1034-1040.

- 626 19. Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J *et al*: **Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.** *Blood* 2015, **125**(7):1137-1145.
- 627
- 628
- 629 20. Khan J, Lieberman JA, Lockwood CM: **Variability in, variability out: best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs.** *Clin Chem Lab Med* 2017, **55**(5):608-621.
- 630
- 631
- 632 21. Liu A, Tetzlaff MT, Vanbelle P, Elder D, Feldman M, Tobias JW, Sepulveda AR, Xu X: **MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues.** *Int J Clin Exp Pathol* 2009, **2**(6):519-527.
- 633
- 634
- 635 22. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, Miller CJ, West CM: **Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation.** *Br J Cancer* 2012, **107**(4):684-694.
- 636
- 637
- 638 23. Eastel JM, Lam KW, Lee NL, Lok WY, Tsang AHF, Pei XM, Chan AKC, Cho WCS, Wong SCC: **Application of NanoString technologies in companion diagnostic development.** *Expert Rev Mol Diagn* 2019, **19**(7):591-598.
- 639
- 640
- 641 24. Leichter AL, Purcell RV, Sullivan MJ, Eccles MR, Chatterjee A: **Multi-platform microRNA profiling of hepatoblastoma patients using formalin fixed paraffin embedded archival samples.** *Gigascience* 2015, **4**:54.
- 642
- 643
- 644 25. Kolbert CP, Feddersen RM, Rakhshan F, Grill DE, Simon G, Middha S, Jang JS, Simon V, Schultz DA, Zschunke M *et al*: **Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues.** *PLoS One* 2013, **8**(1):e52517.
- 645
- 646
- 647 26. Chatterjee A, Leichter AL, Fan V, Tsai P, Purcell RV, Sullivan MJ, Eccles MR: **A cross comparison of technologies for the detection of microRNAs in clinical FFPE samples of hepatoblastoma patients.** *Sci Rep* 2015, **5**:10438.
- 648
- 649
- 650 27. Godoy PM, Barczak AJ, DeHoff P, Srinivasan S, Etheridge A, Galas D, Das S, Erle DJ, Laurent LC: **Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms.** *Cell Rep* 2019, **29**(12):4212-4222 e4215.
- 651
- 652
- 653 28. Baraniskin A, Kuhnenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zollner H, Reinacher-Schick A, Schmiegel W *et al*: **Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.** *Blood* 2011, **117**(11):3140-3146.
- 654
- 655
- 656
- 657 29. Baraniskin A, Kuhnenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W, Hahn S, Schroers R: **Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma.** *Neuro Oncol* 2012, **14**(1):29-33.
- 658
- 659
- 660 30. Baraniskin A, Zaslavska E, Nopel-Dunnebacke S, Ahle G, Seidel S, Schlegel U, Schmiegel W, Hahn S, Schroers R: **Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.** *Neuro Oncol* 2016, **18**(3):361-367.
- 661
- 662
- 663
- 664 31. Baraniskin A, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, Schlegel U, Schmiegel W *et al*: **MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.** *J Neurooncol* 2018, **137**(3):463-468.
- 665
- 666
- 667 32. Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E: **Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas.** *Neuro Oncol* 2011, **13**(10):1090-1098.
- 668
- 669
- 670 33. Yang K, Wang S, Cheng Y, Tian Y, Hou J: **Role of miRNA-21 in the diagnosis and prediction of treatment efficacy of primary central nervous system lymphoma.** *Oncol Lett* 2019, **17**(3):3475-3481.
- 671
- 672
- 673 34. Mao X, Sun Y, Tang J: **Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma.** *Neurol Sci* 2014, **35**(2):233-238.
- 674
- 675 35. Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A *et al*: **Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.** *Eur J Cancer* 2015, **51**(3):382-390.
- 676
- 677

- 678 36. Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, Hayano A, Yamanaka R:
679 **MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising**
680 **prognostic marker in primary central nervous system lymphoma.** *PLoS One* 2019,
681 **14(1):e0210400.**
- 682 37. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuurin E,
683 Kluin P, van den Berg A: **Specific expression of miR-17-5p and miR-127 in testicular and**
684 **central nervous system diffuse large B-cell lymphoma.** *Mod Pathol* 2009, **22(4):547-555.**
- 685 38. Drusco A, Bottoni A, Lagana A, Acunzo M, Fassan M, Cascione L, Antenucci A, Kumchala P,
686 Vicentini C, Gardiman MP *et al*: **A differentially expressed set of microRNAs in cerebro-**
687 **spinal fluid (CSF) can diagnose CNS malignancies.** *Oncotarget* 2015, **6(25):20829-20839.**
- 688 39. Zheng J, Xu J, Ma S, Sun X, Geng M, Wang L: **Clinicopathological study of gene**
689 **rearrangement and microRNA expression of primary central nervous system diffuse large**
690 **B-cell lymphomas.** *Int J Clin Exp Pathol* 2013, **6(10):2048-2055.**
- 691 40. Bodor C, Alpar D, Marosvari D, Galik B, Rajnai H, Batai B, Nagy A, Kajtar B, Burjan A, Deak B *et*
692 *al*: **Molecular Subtypes and Genomic Profile of Primary Central Nervous System**
693 **Lymphoma.** *J Neuropathol Exp Neurol* 2020, **79(2):176-183.**
- 694 41. Waggott DM: **NanoStringNorm: Normalize NanoString miRNA and mRNA Data.**
695 <https://CRAN.R-project.org/package=NanoStringNorm>, Accessed 7 August 2020.
- 696 42. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: **limma powers differential**
697 **expression analyses for RNA-sequencing and microarray studies.** *Nucleic Acids Res* 2015,
698 **43(7):e47.**
- 699 43. Law CW, Chen Y, Shi W, Smyth GK: **voom: Precision weights unlock linear model analysis**
700 **tools for RNA-seq read counts.** *Genome Biol* 2014, **15(2):R29.**
- 701 44. Phipson B, Lee S, Majewski IJ, Alexander WS, Smyth GK: **Robust Hyperparameter Estimation**
702 **Protects against Hypervariable Genes and Improves Power to Detect Differential**
703 **Expression.** *Ann Appl Stat* 2016, **10(2):946-963.**
- 704 45. Kaiser S, Santamaria R, Khamiakova T, Sill M, Theron R, Quintales L, Leisch F, De Troyer E:
705 **biclust: BiCluster Algorithms.** <https://CRAN.R-project.org/package=biclust>, Accessed 7
706 **August 2020.**
- 707 46. Fan Y, Xia J: **miRNet-Functional Analysis and Visual Exploration of miRNA-Target**
708 **Interactions in a Network Context.** *Methods Mol Biol* 2018, **1819:215-233.**
- 709 47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A,
710 Pomeroy SL, Golub TR, Lander ES *et al*: **Gene set enrichment analysis: a knowledge-based**
711 **approach for interpreting genome-wide expression profiles.** *Proc Natl Acad Sci U S A* 2005,
712 **102(43):15545-15550.**
- 713 48. Therneau TM, Lumley T, Atkinson E, Crowson C: **survival: Survival Analysis.** [https://CRAN.R-](https://CRAN.R-project.org/package=survival)
714 [project.org/package=survival](https://CRAN.R-project.org/package=survival), Accessed 7 August 2020.
- 715 49. Kassambara A, Kosinski M, Biecek P, Scheipl F: **survminer: Drawing Survival Curves using**
716 **'ggplot2'.** <https://CRAN.R-project.org/package=survminer>, Accessed 7 August 2020.
- 717 50. Reinsborough CW, Ipas H, Abell NS, Nottingham RM, Yao J, Devanathan SK, Shelton SB,
718 Lambowitz AM, Xhemalce B: **BCDIN3D regulates tRNAHis 3' fragment processing.** *PLoS*
719 *Genet* 2019, **15(7):e1008273.**
- 720 51. Dedhia P, Tarale S, Dhongde G, Khadapkar R, Das B: **Evaluation of DNA extraction methods**
721 **and real time PCR optimization on formalin-fixed paraffin-embedded tissues.** *Asian Pac J*
722 *Cancer Prev* 2007, **8(1):55-59.**
- 723 52. Ribeiro-Silva A, Zhang H, Jeffrey SS: **RNA extraction from ten year old formalin-fixed**
724 **paraffin-embedded breast cancer samples: a comparison of column purification and**
725 **magnetic bead-based technologies.** *BMC Mol Biol* 2007, **8:118.**
- 726 53. Klopffleisch R, Weiss AT, Gruber AD: **Excavation of a buried treasure--DNA, mRNA, miRNA**
727 **and protein analysis in formalin fixed, paraffin embedded tissues.** *Histol Histopathol* 2011,
728 **26(6):797-810.**

- 729 54. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K: **Analysis of chemical modification**
730 **of RNA from formalin-fixed samples and optimization of molecular biology applications for**
731 **such samples.** *Nucleic Acids Res* 1999, **27**(22):4436-4443.
- 732 55. Kokkat TJ, Patel MS, McGarvey D, LiVolsi VA, Baloch ZW: **Archived formalin-fixed paraffin-**
733 **embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA,**
734 **and protein.** *Biopreserv Biobank* 2013, **11**(2):101-106.
- 735 56. Giusti L, Angeloni C, Lucacchini A: **Update on proteomic studies of formalin-fixed paraffin-**
736 **embedded tissues.** *Expert Rev Proteomics* 2019, **16**(6):513-520.
- 737 57. Zheng B, Xi Z, Liu R, Yin W, Sui Z, Ren B, Miller H, Gong Q, Liu C: **The Function of MicroRNAs**
738 **in B-Cell Development, Lymphoma, and Their Potential in Clinical Practice.** *Front Immunol*
739 2018, **9**:936.
- 740 58. Esquela-Kerscher A, Slack FJ: **Oncomirs - microRNAs with a role in cancer.** *Nat Rev Cancer*
741 2006, **6**(4):259-269.
- 742 59. Rupaimoole R, Slack FJ: **MicroRNA therapeutics: towards a new era for the management of**
743 **cancer and other diseases.** *Nat Rev Drug Discov* 2017, **16**(3):203-222.
- 744 60. Han W, Cui H, Liang J, Su X: **Role of MicroRNA-30c in cancer progression.** *J Cancer* 2020,
745 **11**(9):2593-2601.
- 746 61. Selcuklu SD, Donoghue MT, Spillane C: **miR-21 as a key regulator of oncogenic processes.**
747 *Biochem Soc Trans* 2009, **37**(Pt 4):918-925.
- 748 62. Liu K, Du J, Ruan L: **MicroRNA-21 regulates the viability and apoptosis of diffuse large B-cell**
749 **lymphoma cells by upregulating B cell lymphoma-2.** *Exp Ther Med* 2017, **14**(5):4489-4496.
- 750 63. Tamaddon G, Geramizadeh B, Karimi MH, Mowla SJ, Abroun S: **miR-4284 and miR-4484 as**
751 **Putative Biomarkers for Diffuse Large B-Cell Lymphoma.** *Iran J Med Sci* 2016, **41**(4):334-339.
- 752 64. Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK: **MicroRNA-**
753 **21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in**
754 **diffuse large B-cell lymphoma.** *Oncotarget* 2015, **6**(17):15035-15049.
- 755 65. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattani H, Enver T, Mager
756 R, Boultonwood J *et al*: **MicroRNA expression distinguishes between germinal center B cell-**
757 **like and activated B cell-like subtypes of diffuse large B cell lymphoma.** *Int J Cancer* 2007,
758 **121**(5):1156-1161.
- 759 66. Song J, Shao Q, Li C, Liu H, Li J, Wang Y, Song W, Li L, Wang G, Shao Z *et al*: **Effects of**
760 **microRNA-21 on apoptosis by regulating the expression of PTEN in diffuse large B-cell**
761 **lymphoma.** *Medicine (Baltimore)* 2017, **96**(39):e7952.
- 762 67. Li J, Fu R, Yang L, Tu W: **miR-21 expression predicts prognosis in diffuse large B-cell**
763 **lymphoma.** *Int J Clin Exp Pathol* 2015, **8**(11):15019-15024.
- 764 68. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-
765 Cardo C, Lowe SW, Hannon GJ *et al*: **A microRNA polycistron as a potential human**
766 **oncogene.** *Nature* 2005, **435**(7043):828-833.
- 767 69. Tagawa H, Seto M: **A microRNA cluster as a target of genomic amplification in malignant**
768 **lymphoma.** *Leukemia* 2005, **19**(11):2013-2016.
- 769 70. Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A: **The Myc-**
770 **miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel**
771 **lymphomagenic feed-forward loop.** *Blood* 2013, **122**(26):4220-4229.
- 772 71. Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, Saunders NJ, Pezzella F,
773 Boultonwood J, Wainscoat JS *et al*: **Expression of microRNAs in diffuse large B cell lymphoma**
774 **is associated with immunophenotype, survival and transformation from follicular**
775 **lymphoma.** *J Cell Mol Med* 2009, **13**(7):1248-1260.
- 776 72. Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S, Briones J, Natkunam
777 Y, Sehn LH, Gascoyne RD *et al*: **MicroRNAs are independent predictors of outcome in diffuse**
778 **large B-cell lymphoma patients treated with R-CHOP.** *Clin Cancer Res* 2011, **17**(12):4125-
779 4135.

- 780 73. Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J,
781 Boyle M *et al*: **Comprehensive miRNA sequence analysis reveals survival differences in**
782 **diffuse large B-cell lymphoma patients.** *Genome Biol* 2015, **16**:18.
- 783 74. Zhong H, Xu L, Zhong JH, Xiao F, Liu Q, Huang HH, Chen FY: **Clinical and prognostic**
784 **significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-**
785 **embedded tissue of patients with diffuse large B-cell lymphoma.** *Exp Ther Med* 2012,
786 **3**(5):763-770.
- 787 75. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: **Accumulation of**
788 **miR-155 and BIC RNA in human B cell lymphomas.** *Proc Natl Acad Sci U S A* 2005,
789 **102**(10):3627-3632.
- 790 76. Huang X, Shen Y, Liu M, Bi C, Jiang C, Iqbal J, McKeithan TW, Chan WC, Ding SJ, Fu K:
791 **Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse**
792 **large B-cell lymphoma.** *Am J Pathol* 2012, **181**(1):26-33.
- 793 77. Wang X, Wang K, Han L, Zhang A, Shi Z, Zhang K, Zhang H, Yang S, Pu P, Shen C *et al*: **PRDM1**
794 **is directly targeted by miR-30a-5p and modulates the Wnt/beta-catenin pathway in a**
795 **Dkk1-dependent manner during glioma growth.** *Cancer Lett* 2013, **331**(2):211-219.
- 796 78. Pasqualucci L, Dalla-Favera R: **SnapShot: diffuse large B cell lymphoma.** *Cancer Cell* 2014,
797 **25**(1):132-132 e131.
- 798 79. Sehn LH, Gascoyne RD: **Diffuse large B-cell lymphoma: optimizing outcome in the context of**
799 **clinical and biologic heterogeneity.** *Blood* 2015, **125**(1):22-32.
- 800 80. Vermaat JS, Pals ST, Younes A, Dreyling M, Federico M, Aurer I, Radford J, Kersten MJ, Eha
801 Lymphoma Group aSWGotEHA: **Precision medicine in diffuse large B-cell lymphoma: hitting**
802 **the target.** *Haematologica* 2015, **100**(8):989-993.
- 803 81. Takashima Y, Sasaki Y, Hayano A, Homma J, Fukai J, Iwadata Y, Kajiwara K, Ishizawa S,
804 Hondoh H, Tokino T *et al*: **Target amplicon exome-sequencing identifies promising diagnosis**
805 **and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central**
806 **oncopathways in primary central nervous system lymphoma.** *Oncotarget* 2018,
807 **9**(44):27471-27486.
- 808 82. Mendez JS, Grommes C: **Treatment of Primary Central Nervous System Lymphoma: From**
809 **Chemotherapy to Small Molecules.** *Am Soc Clin Oncol Educ Book* 2018, **38**:604-615.
- 810 83. Madden E, Logue SE, Healy SJ, Manie S, Samali A: **The role of the unfolded protein response**
811 **in cancer progression: From oncogenesis to chemoresistance.** *Biol Cell* 2019, **111**(1):1-17.
- 812 84. Ferreri AJM: **Secondary CNS lymphoma: the poisoned needle in the haystack.** *Ann Oncol*
813 2017, **28**(10):2335-2337.
- 814 85. Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Scharzt D, Codega P, Nichol D, Clark
815 O, Hsieh WY *et al*: **Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS**
816 **Lymphoma.** *Cancer Discov* 2017, **7**(9):1018-1029.
- 817 86. Vallee A, Lecarpentier Y, Vallee JN: **Hypothesis of Opposite Interplay Between the Canonical**
818 **WNT/beta-catenin Pathway and PPAR Gamma in Primary Central Nervous System**
819 **Lymphomas.** *Curr Issues Mol Biol* 2019, **31**:1-20.
- 820 87. Jung YS, Park JI: **Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond**
821 **beta-catenin and the destruction complex.** *Exp Mol Med* 2020, **52**(2):183-191.

822

823

824 **Figure captions**

825 **Figure 1.** Sample characteristics and general expression patterns. **a)** Total number of primary
826 and secondary central nervous system lymphoma samples categorized by molecular subtypes.
827 **b)** Median normalized expression of miRNAs in PCNSL (x-axis) and SCNSL (y-axis)
828 samples. Both axes are \log_{10} based, and the hexagon color scale shows the number of
829 miRNAs falling into a particular median expression range. As can be seen on the plot (bright
830 yellow hexagon in the bottom left corner), a large number of miRNAs had a 0 or near 0
831 expression in both sample types. The Spearman correlation of PCNSL and SCNSL values is
832 0.89.

833 **Figure 2.** Differential expression analysis between sample groups. **a)** Volcano-plot of
834 differential expression results comparing secondary and primary samples, the GC and ABC or
835 UC and ABC sample groups. The x-axis shows the \log_2 fold change of a specific miRNA,
836 while the y-axis shows the $-\log_{10}$ transformed FDR corrected p-value. **b)** Volcano-plot of
837 differential expression results comparing mutated and non-mutated samples for a specific
838 gene, where the color of the dots correlates with the number of mutated samples. As in panel
839 **a)** x-axis shows the \log_2 fold change of a specific miRNA, while the y-axis shows the $-\log_{10}$
840 transformed FDR corrected p-value.

841 **Figure 3.** Principal component analysis of miRNA expression patterns of all samples, after
842 removing potential batch effects from the normalized and voom transformed data. The shape
843 of the points shows the primary or secondary disease category, while the color corresponds to
844 the molecular subtype.

845 **Figure 4.** Unsupervised clustering of samples using binary (ON/OFF) miRNA expression
846 patterns. The heatmap shows the binary expression pattern of miRNAs that were considered
847 expressed in at least one sample. Columns correspond to samples, while rows correspond to a

848 specific miRNA. Yellow tiles show expressed, purple tiles show non-expressed miRNAs. On
849 top of the heatmap a hierarchical clustering tree shows the relationship between samples.
850 miRNAs that were not expressed in any of the samples are not shown.

851 **Figure 5.** Unsupervised clustering of samples using normalized miRNA expression patterns.
852 The heatmap shows the k-means clustering of miRNAs after normalization, voom
853 transformation and batch effect removal. Columns correspond to samples, while rows
854 correspond to a specific miRNA. Heatmap colors show expression intensity. We removed the
855 largest miRNA cluster (Mcluster2) from the visualization as it contained mainly miRNAs
856 with zero or very low expression.

857 **Figure 6.** Gene set enrichment analysis. MSigDB pathways deregulated in specific
858 comparisons, based on the differential expression patterns of miRNAs, from PRDM1 mutated
859 and non-mutated or secondary and primary samples. Additionally, the figure shows the
860 putatively deregulated pathways using the 19 miRNAs showing a significant association with
861 the unknown “small cluster” based on the unsupervised clustering of expression data. The x
862 axis shows the $-\log_{10}$ transformed, FDR corrected Fisher-test p-values, the y axis lists the
863 deregulated MSigDB cancer hallmarks, and the dot size is proportional to the Fisher-test odds
864 value. The dot colors correspond to the three different categories investigated (*PRDM1*
865 mutated vs wild-type, SCNSL vs PCNSL and the unknown small cluster). The light red
866 background of the “Unknown small cluster” facet indicates that pathways in this analysis are
867 upregulated, while pathways in the other two comparisons are downregulated.

868

869

870 **Table 1.**



| <i>Condition</i> | <i>microRNA</i> | <i>log2 fc</i> | <i>FDR</i> | <i>References</i> |
|--------------------------|-------------------|----------------|------------|-----------------------------|
| SCNSL vs. PCNSL | hsa-miR-873-3p | -7,61 | 0,0342768 | - |
| | hsa-miR-6721-5p | -4,74 | 0,0466017 | - |
| | hsa-miR-509-5p | -2,17 | 0,0379788 | - |
| | hsa-miR-454-3p | 2,75 | 0,0342768 | - |
| | hsa-miR-532-3p | 2,92 | 0,0401021 | - |
| | hsa-miR-301a-3p | 3,13 | 0,0342768 | - |
| | hsa-miR-320e | 3,51 | 0,0366852 | - |
| | hsa-miR-374b-5p | 3,53 | 0,0342768 | - |
| | hsa-miR-421 | 3,54 | 0,0342768 | - |
| | hsa-miR-30c-5p | 3,55 | 0,0342768 | [31, 32] |
| | hsa-miR-361-5p | 3,68 | 0,0342768 | - |
| | hsa-miR-133a-3p | 3,75 | 0,0342768 | - |
| | hsa-miR-551b-3p | 3,75 | 0,0342768 | - |
| | hsa-miR-630 | 4,21 | 0,0342768 | - |
| | hsa-miR-1290 | 4,68 | 0,0342768 | - |
| | hsa-miR-574-5p | 4,69 | 0,0342768 | - |
| | hsa-miR-107 | 4,71 | 0,0469009 | - |
| | hsa-miR-362-5p | 4,87 | 0,0036679 | - |
| | hsa-miR-1246 | 4,92 | 0,0499940 | - |
| | hsa-miR-1915-3p | 5,05 | 0,0342768 | - |
| | hsa-miR-148b-3p | 5,21 | 0,0364880 | - |
| | hsa-miR-1285-5p | 5,28 | 0,0036679 | - |
| | hsa-miR-21-5p | 5,33 | 0,0036679 | [16, 28, 29, 33, 34, 62-66] |
| | hsa-miR-7-5p | 5,97 | 0,0342768 | - |
| | hsa-miR-423-5p | 6,75 | 0,0012532 | - |
| | hsa-miR-32-5p | 6,75 | 0,0117086 | - |
| | hsa-let-7e-5p | 7,27 | 0,0014054 | - |
| | hsa-miR-19a-3p | 7,33 | 0,0036679 | [68-71] |
| | hsa-miR-106b-5p | 7,84 | 0,0006885 | [68-71] |
| | hsa-miR-18a-5p | 8,59 | 0,0000234 | [68-72] |
| | hsa-miR-4516 | 8,74 | 0,0108205 | - |
| | GC vs. ABC | hsa-miR-222-3p | -3,82 | 0,0280039 |
| | hsa-miR-522-3p | -2,34 | 0,0455441 | - |
| | hsa-miR-155-5p | -2,26 | 0,0280039 | [16, 19, 64, 65, 71, 73-76] |
| | hsa-miR-92a-3p | 4,70 | 0,0005669 | - |
| UC vs. ABC | hsa-miR-522-3p | -3,06 | 0,0097304 | - |
| | hsa-miR-455-5p | -2,09 | 0,0097304 | - |
| | hsa-miR-454-3p | -2,12 | 0,0114100 | - |
| PRDMI mut vs. nm | hsa-miR-551a | -1,27 | 0,0427852 | - |
| | hsa-miR-107 | 1,42 | 0,0427852 | - |
| | hsa-miR-195-5p | 1,53 | 0,0427852 | - |
| | hsa-miR-526b-5p | 1,69 | 0,0427852 | - |
| | hsa-miR-376a-3p | 1,87 | 0,0427852 | - |
| | hsa-miR-130a-3p | 2,34 | 0,0428542 | - |
| | hsa-miR-548y | 2,89 | 0,0068707 | - |
| | hsa-miR-30a-5p | 3,61 | 0,0427852 | [77] |
| MYC mut vs. nm | hsa-miR-411-5p | -2,50 | 0,0042775 | - |
| CARD11 mut vs. nm | hsa-miR-379-5p | -3,55 | 0,0186781 | - |



871


872 **Table captions**



873 **Table 1.** Differentially expressed miRNAs between primary and secondary central nervous
874 system lymphomas, molecular subtypes and in association to mutation status. The columns
875 show the tested condition, the log₂ fold-change, the FDR and the literature references if
876 known. Abbreviations: ABC, activated B-cell type; GC, germinal center B-cell type; mut,
877 mutated; nm, non-mutated; PCNSL, primary central nervous system lymphoma; SCNSL,
878 secondary central nervous system lymphoma; UC, unclassified; vs., versus.

879









sample_53
sample_35
sample_34
sample_34
sample_34
sample_90
sample_51
sample_68
sample_102
sample_21
sample_89
sample_85
sample_6
sample_71
sample_67
sample_69
sample_20
sample_11
sample_61
sample_14
sample_25
sample_103
sample_32
sample_38
sample_99
sample_64
sample_73
sample_56
sample_70
sample_16
sample_29
sample_2
sample_40
sample_60
sample_66
sample_71
sample_9
sample_22
sample_22
sample_65
sample_58
sample_87
sample_46
sample_46
sample_84
sample_91
sample_49
sample_43
sample_4
sample_42
sample_38
sample_78
sample_78
sample_104
sample_45
sample_11
sample_28
sample_17
sample_47
sample_30
sample_41
sample_32
sample_36
sample_29
sample_74
sample_33
sample_57
sample_72
sample_37
sample_39
sample_96

